175 related articles for article (PubMed ID: 28215027)
1. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
3. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
Gridelli C; Ferrara C; Guerriero C; Palazzo S; Grasso G; Pavese I; Satta F; Bajetta E; Cortinovis D; Barbieri F; Gebbia V; Grossi F; Novello S; Baldini E; Gasparini G; Latino W; Durante E; Giustini L; Negrini C
J Thorac Oncol; 2007 Jun; 2(6):475-80. PubMed ID: 17545841
[TBL] [Abstract][Full Text] [Related]
4. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
[TBL] [Abstract][Full Text] [Related]
5. Costs of non-small cell lung cancer in the Netherlands.
van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
[TBL] [Abstract][Full Text] [Related]
6. Changing costs of metastatic non small cell lung cancer in the Netherlands.
Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
8. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
9. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
10. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
12. Economics of the clinical management of lung cancer in France: an analysis using a Markov model.
Chouaïd C; Molinier L; Combescure C; Daurès JP; Housset B; Vergnenègre A
Br J Cancer; 2004 Jan; 90(2):397-402. PubMed ID: 14735183
[TBL] [Abstract][Full Text] [Related]
13. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
14. Cost-of-illness study for non-small-cell lung cancer using real-world data.
Seung SJ; Hurry M; Hassan S; Walton RN; Evans WK
Curr Oncol; 2019 Apr; 26(2):102-107. PubMed ID: 31043811
[TBL] [Abstract][Full Text] [Related]
15. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
16. Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial.
Hornberger J; Hirsch FR; Li Q; Page RD
Lung Cancer; 2015 May; 88(2):223-30. PubMed ID: 25804732
[TBL] [Abstract][Full Text] [Related]
17. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
[TBL] [Abstract][Full Text] [Related]
20. The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.
Ihbe-Heffinger A; Paessens B; Berger K; Shlaen M; Bernard R; von Schilling C; Peschel C
Support Care Cancer; 2013 Jun; 21(6):1665-75. PubMed ID: 23338228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]